- Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
- Antipsychotics for treatment of delirium in hospitalised non‐ICU patients
- Anxiolytics for smoking cessation
- Aripiprazole for autism spectrum disorders (ASD)
- Aripiprazole for schizophrenia
- Aripiprazole versus other atypical antipsychotics for schizophrenia
- Aripiprazole versus placebo for schizophrenia
- Aripiprazole versus typical antipsychotic drugs for schizophrenia
- Aromatherapy for dementia
- Art therapy for schizophrenia or schizophrenia-like illnesses
- 'As required' medication regimens for seriously mentally ill people in hospital
- Aspirin for vascular dementia
- Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease
- Atypical antipsychotics for aggression and psychosis in Alzheimer's disease
- Atypical antipsychotics for people with both schizophrenia and depression
- Auditory integration training and other sound therapies for autism spectrum disorders (ASD)
- Auricular acupuncture for cocaine dependence
- Aversive smoking for smoking cessation
- Ayurvedic medicine for schizophrenia
- Azapirones for generalized anxiety disorder
The Cochrane Database of Systematic Reviews is considered the gold standard for evidence-based medicine. Essential Evidence Plus includes the latest and most up-to-date summaries of systematic reviews from the Cochrane Library, which are the most rigorous and reliable evaluations of medical therapies available. You’ll find summarized evaluations of the world’s best literature on the effectiveness of therapy for 3,300+ clinical problems.